Researchers from Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. have described dual CDK4/cyclin D1 and cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
Shanghai Pharmaceuticals Holding Co. Ltd. has reported interleukin-17A (IL-17A) inhibitors that are potentially useful for the treatment of psoriasis, rheumatoid arthritis, spondyloarthritis, hidradenitis suppurativa, psoriatic arthritis and uveitis.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed heterocyclic compounds and their antibody-drug conjugates reported to be useful for the treatment of cancer.
Ignis Therapeutics (Suzhou) Co. Ltd. has synthesized new tetrahydroisoquinoline compounds acting as dopamine D1 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of apathy, Parkinson’s disease, Huntington’s disease, dystonia, Alzheimer’s disease, neuropathic pain, psychosis and sleep disorder and among others.
Prospect Therapeutics Inc. has patented new nitrogen-containing heterocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors potentially useful for the treatment of cancer.
Chengdu Chipscreen Pharmaceutical Ltd. has divulged new 2-acylglycerol O-acyltransferase 2 (MGAT2, MOGAT2) inhibitors potentially useful for the treatment of obesity.
Zealand Pharma A/S has identified new interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of Crohn’s disease, ulcerative colitis, psoriasis and psoriatic arthritis.
Shanghai Huilun Pharmaceutical Co. Ltd. has identified new angiotensin AT2 receptor antagonists potentially useful for the treatment of neuropathic pain.
Chengdu Shibeikang Biological Medicine Technology Co. Ltd. has patented new platelet adhesion inhibitors reported to be useful for the treatment of cardiovascular and cerebrovascular disorders.
RSS